Immunological drivers and new therapeutic pathways

Endometrial carcinoma is increasingly becoming the focus of modern tumor immunology as an immunologically characterized tumor disease. Molecular subtypes, microbiome interactions and a highly dynamic tumor immunological microenvironment are opening up new diagnostic and therapeutic options. Advances in multi-omics analytics, immunobiology and AI-supported diagnostics are fundamentally changing care and marking the transition to precision oncology.